ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

プラゼパム

Prazepam

HCID 4890
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
2955-38-6
標準SMILES
O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1
InChIKey
MWQCHHACWWAQLJ-UHFFFAOYSA-N
分子式
C19H17ClN2O
平均分子量
324.8 g/mol
単同位体質量
324.1029409

概要

Prazepam is a benzodiazepine.

名称と識別子

優先名称
Prazepam
IUPAC
7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
現地名
プラゼパム
英語名
PRAZEPAM
分子式
C19H17ClN2O
分子量
324.8

名称と別名

prazepamCentraxDemetrinTrepidan2955-38-6PrazepamumW 4020Prazepam civDTXSID40211812H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-oneW-4020
名称をさらに表示
7-クロロ-1-シクロプロピルメチル-5-(フェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オンセントラッキスセダプランプラゼパムベルストラン1-(シクロプロピルメチル)-5-(フェニル)-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン1-(シクロプロピルメチル)-5-[フェニル]-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン7-クロロ-1-(シクロプロピルメチル)-1,3-ジヒドロ-5-フェニル-2H-1,4-ベンゾジアゼピン-2-オンプラゼパム (JP17)7-クロロ-1-(シクロプロピルメチル)-5-フェニル-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピン-2-オンw4020K-373SettimaPrazeneVerstranSedapran
NSC-277179Q30VCC064MDTXCID1011817-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-oneMono DemetrinRefChem:55907N05BA11

データベース識別子

CAS
2955-38-6
PubChem CID
4890
DTXSID
DTXSID4021181
ChEMBL
CHEMBL969
ChEBI
CHEBI:8362
UNII
Q30VCC064M
EC Number
220-975-8
Nikkaji
J3.397I

物性

構造計算による物性補完中

XLogP
3.6
極性表面積
32.7 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
3
重原子数
23
形式電荷
0
複雑度
482

実験および物理化学的性質

Drugs · 6 件

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Benzodiazepines

LogP · 2 件

3.73

3.31

Solubility3.99e-03 g/L
Human Drugs · 3 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 件

145-146 °C

145 - 146 °C

Physical DescriptionSolid
Collision Cross Section174 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

融点
145 · 145-146°
沸点
538.5 · 538.5±50.0 °C(Predicted)
比重(密度)
1.166 · 1.1660 (rough estimate)
屈折率
1.579 · 1.5790 (estimate)
闪点
11 °C · 11 °C
貯蔵温度
2 · 2-8°C
溶解性
0.25 g · 0.25 g をアルコール R に溶解し、同じ溶媒で 10 mL に希釈します。溶液は透明 (2.2.1) で無色 (2.2.2、方法 II) でした。
外見
Solid
酸解離定数(Pka)
2.94 · pKa 2.94 (Uncertain)
色
White to Off-White
水溶解度
9.095 mg/L · 9.095mg/L(25℃)
主な用途
医薬品(低分子化合物)
InChI
1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
InChIKey
MWQCHHACWWAQLJ-UHFFFAOYSA-N
SMILES
Clc1ccc2N(CC3CC3)C(=O)CN=C(c4ccccc4)c2c1
EPAの化学物質情報
2 H-1,4-Benzodiazepin-2-one, · 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl- (2955-38-6)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

Warning

H336 (66.7%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure; Narcotic effects]

P203, P260, P261, P263, P264, P270, P271, P280, P304+P340, P318, P319, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

DEA schedule IV controlled substance

2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Human health tier I assessment
Hazard Classes and CategoriesSTOT SE 3 (66.7%)

毒性情報

Treatment · 1 件

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Exposure RoutesOral
Toxicity Summary · 1 件

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

Signs and SymptomsSymptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
Carcinogen Classification · 6 件

Prazepam

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 66: (1996) Some Pharmaceutical Drugs

1996

1996

3, not classifiable as to its carcinogenicity to humans. (L135)

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Prazepam

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

wgk
2
rtecs
DF2368000
ridadr
3249
hs_code
2933910000
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
22-24/25-45-36/37-16-7
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
STOT SE 3
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 3 件

N05BA11

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.

Mechanism of Action · 1 件

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

Biological Half-Life36-200 hours
Metabolism/Metabolites · 2 件

Hepatic.

Hepatic. Prazepam is metabolised into descyclopropylmethylprazepam (also known as desmethyldiazepam) and 3-hydroxyprazepam which is further metabolised into oxazepam. [Wikipedia] Half Life: 36-200 hours

MeSH Pharmacological Classification · 2 件

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Cellular LocationsMembrane

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >25

For the treatment of anxiety disorders.

Use ClassificationPharmaceuticals
応用分野 · 6 件

用途生化学用試薬、神経作用物質。

用途ベンゾジアゼピン系化合物で す。GABA 受容体に作用し、中枢神経抑制作 用を示します。作用時間は、長時間型とされ ています。

用途ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は、長時間型とされ ています。

説明Prazepam (Item No. 18358) is an analytical reference material categorized as a benzodiazepine. Prazepam is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

使用Sedative-hypnotic.

一般的な説明Prazepam, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one(Verstran), has a long overall half-life. Extensive N-dealkylationoccurs to yield active nordazepam. 3-Hydroxylation ofboth prazepam and nordazepam occurs.

上流・下流製品情報

上流原料

水素化リチウムアルミニウムPhthalimido Acetyl Chlorideヒドラジン一水和物二酸化マンガンシクロプロパンカルボニルクロリド2-アミノ-5-クロロベンゾフェノン

関連反応

1 件
反応記録を作成
HRID 704543 の反応式
HRID 704543反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート